Kanker prostat téh kanker nu panglobana kadua di lalaki di sakuliah dunya, kira-kira 1.276 juta kasus anyar nu dilaporkeun dina taun 2018, nu ngawakilan 7,1% tina sakabéh kasus kanker di lalaki.
Tingkat maotna kanker prostat ogé luhur, diperkirakeun aya 37.005 maotna di sakuliah dunya dina taun 2018.
Tapi, tingkat maotna béda-béda dumasar wewengkon, Afrika Kulon boga résiko pangluhurna kalima pikeun maotna kanker prostat di dunya, sarta Nigeria boga populasi jeung ékonomi panglobana di wewengkon ieu.
Di Nigeria, kanker prostat téh kanker nu paling umum jeung nu paling matak maot pikeun lalaki, kira-kira 32,8 kasus jeung 16,3 maotna per 100.000 lalaki.
Ieu leuwih ti dua kali lipat tina angka maotna di Amérika Kalér.
Kasakit ieu teu gancang kapanggih, sumber daya pikeun panyaringan jeung panyingkepan kawates, sarta kurangna dokuméntasi jeung laporan kasus, nyababkeun tingkat maotna nu luhur di Nigeria.
Di Amérika Sarikat, kanker prostat téh nu kadua nu paling umum ngabalukarkeun maot lalaki alatan kanker, kira-kira 40.000 lalaki maot tina panyakit ieu unggal taun.
Tingkat maotna kanker prostat geus turun saeutik-saeutik ti mimiti taun 1990-an, tapi tetep jadi masalah kaséhatan nu gedé.
Sacara umum, kanker prostat téh panyakit nu bisa ngabalukarkeun maot, utamana di daérah nu kurang aya perawatan médis jeung sumber daya pikeun panyaringan.
Tapi, lamun diwanohkeun jeung diubaran ti mimiti, bisa ngaronjatkeun hasilna jeung ngurangan angka maotna.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Bantahan: masalah médis']
['Situs wéb ieu ngan keur tujuan pendidikan jeung informasi, lain pikeun méré naséhat atawa jasa profésional.']
['Informasi nu disadiakeun di dieu teu kudu dipaké pikeun nangtukeun atawa ngubaran masalah kaséhatan atawa panyakit.']
['Punten perhatikeun yén jaringan saraf nu ngahasilkeun jawaban kana pananya, teu akurat lamun ngeunaan eusi numeris. contona, jumlah jalma nu didiagnosis kalawan panyakit husus.']
['Salawasna ménta naséhat ti dokter atawa panyadia kaséhatan nu mumpuni séjénna ngeunaan kaayaan médis. Ulah ngalalaworakeun naséhat médis profésional atawa nunda néangan éta kusabab hal nu geus maca dina ramatloka ieu. Lamun anjeun mikir anjeun bisa jadi boga kaayaan darurat médis, nelepon 911 atawa indit ka kamar darurat pangdeukeutna langsung.']
['Bantahan: hak cipta']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (DMCA) nyadiakeun jalan pikeun nu boga hak cipta nu percaya yén bahan nu muncul di Internet ngalanggar hak-hakna dina hukum hak cipta AS. ']
['Lamun anjeun percaya yén aya eusi atawa bahan nu disadiakeun dina situs wéb atawa jasa urang ngalanggar hak cipta anjeun, anjeun (atawa agén anjeun) bisa ngirimkeun béwara ka kami pikeun nyuhunkeun eusi atawa bahan éta dipiceun, atawa aksés ka éta diblokir.']
['Bewara kudu dikirimkeun ku email (tempo bagian "Kontak" pikeun alamat email).']
['DMCA merlukeun yén bewara Anjeun tina ngalanggar hak cipta disangka kaasup informasi di handap ieu: (1) pedaran karya nu hak ciptana nu subyek ngalanggar ngaku; (2) pedaran eusi nu disangka ngalanggar jeung informasi cukup pikeun ngidinan urang pikeun nomeran eusi; (3) informasi kontak pikeun anjeun, kaasup alamat anjeun, nomer telepon jeung alamat surélék; (4) pernyataan ku anjeun nu boga kapercayaan alus iman nu eusi dina ragam complaining ngeunaan teu otorisasi ku nu boga hak cipta, atawa agén anak, atawa ku operasi hukum nu mana wae; ']
['(5) pernyataan nu ditandatanganan ku Sadérék, nu ngajamin yén informasi nu aya dina éta surat téh bener jeung Sadérék boga wewenang pikeun ngabéla hak cipta nu diklaim dilanggar.']
['jeung (6) tanda tangan nu nyata atawa éléktronik nu boga hak cipta atawa jalma nu boga wewenang pikeun ngawakilan nu boga hak cipta. ']
['Lamun teu kaasup kabéh informasi di luhur, bisa ngalambatkeun panalungtikan keluhan.']
['Kontak']
['Mangga kirimkeun email ka kami lamun aya pertanyaan/saran.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ngeunaan']
['BioMedLib ngagunakeun komputer otomatis (algoritma mesin-learning) pikeun ngahasilkeun pasangan pertanyaan-jawaban.']
['Urang mimitian ku 35 juta publikasi biomedis tina PubMed/Medline. ogé, kaca web tina RefinedWeb.']
